Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8269483 | 0.88 | PLCG1 (0.46) | PLCG1KMT2AMEN1NOX1MMP2 | |
| SCHEMBL255959 | 0.78 | PLCG1 (0.52) | PLCG1KMT2AMEN1NOX1MMP2 | |
| SCHEMBL30914644 | 0.78 | PLCG1 (0.52) | PLCG1KMT2AMEN1NOX1MMP2 | |
| SCHEMBL5848805 | 0.75 | KEAP1 (0.50) | PLCG1KMT2AMEN1NOX1MMP2 | |
| SCHEMBL13776041 | 0.73 | ALDH1A1 (0.42) | PLCG1MMP9ADAM17CA2CA12 | |
| SCHEMBL1450521 | 0.73 | CA2 (0.33) | CA2 | |
| SCHEMBL22232991 | 0.73 | CA2 (0.40) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL19751546 | 0.73 | CA2 (0.44) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL7352121 | 0.72 | MEN1 (0.41) | PLCG1KMT2AMEN1NOX1MMP2 | |
| SCHEMBL7352122 | 0.72 | MEN1 (0.41) | PLCG1KMT2AMEN1NOX1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583977-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-07-16 | — | — | EP | claimed |
| WO-2024052512-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | WO | claimed |
| CN-114026087-B | Tri-ring compound and preparation method and application thereof | 上海济煜医药科技有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-114026087-A | Tricyclic compound and preparation method and application thereof | 上海济煜医药科技有限公司 | 2022-02-08 | — | — | CN | claimed |
| EP-3630770-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | claimed |
| WO-2018218133-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | claimed |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| WO-2024126453-A1 | NEW SUBSTITUTED INDOLE-2-CARBOXAMIDES AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024089008-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023073641-A9 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| US-20230390237-A1 | IMMUNOMODULATING UREA AZALIDES | ZOETIS SERVICES LLC | 2023-12-07 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390237-A1 | IMMUNOMODULATING UREA AZALIDES | ARG1, IL2, CD209 | PLCG1 1504/4885KMT2A 1719/4885MEN1 1099/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | PLCG1 4085/4885KMT2A 3192/4885MEN1 2386/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | PLCG1 4090/4885KMT2A 3129/4885MEN1 2336/4885 |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK1, JAK3 | PLCG1 2823/4885KMT2A 1977/4885MEN1 4831/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | PLCG1 829/4885KMT2A 2989/4885MEN1 112/4885 |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | PLCG1 1178/4885KMT2A 4331/4885MEN1 4561/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | PLCG1 844/4885KMT2A 3780/4885MEN1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.